But, like Merck two weeks ago, GSK has failed to hit overall survival.
ApexOnco Front Page
Recent articles
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
Kura will see more combo data, while a new contender from Sumitomo emerges.
Genmab quietly reveals pipeline discontinuations and a delay to the son of Darzalex.
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
